Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Portfolio Pulse from Vandana Singh
Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, beating the consensus of $0.46, and sales of $13.28 billion, up 2% year-over-year. The company updated its 2024 revenue forecast to $59.5 billion—$62.5 billion and expects 2024 adjusted EPS of $2.45-$2.65. PFE stock is up 1.60% in premarket trading.
July 30, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer reported better-than-expected Q2 earnings and revenue, and raised its 2024 guidance. The stock is up 1.60% in premarket trading.
Pfizer's better-than-expected Q2 earnings and revenue, along with raised 2024 guidance, are positive indicators for the stock. The premarket increase of 1.60% reflects investor optimism.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100